270 related articles for article (PubMed ID: 19825447)
1. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Kantarjian HM
Hematol Oncol Clin North Am; 2009 Oct; 23(5):949-71, v. PubMed ID: 19825447
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in acute lymphoblastic leukemia.
Jabbour E; O'Brien S; Ravandi F; Kantarjian H
Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
[TBL] [Abstract][Full Text] [Related]
4. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
6. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.
Kantarjian H; Thomas D; Wayne AS; O'Brien S
J Clin Oncol; 2012 Nov; 30(31):3876-83. PubMed ID: 22891271
[No Abstract] [Full Text] [Related]
8. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the management of acute lymphoblastic leukemia.
Levato L; Molica S
Expert Opin Biol Ther; 2018 Feb; 18(2):221-226. PubMed ID: 29310477
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in adult acute lymphoblastic leukemia.
Kantarjian H
Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
[TBL] [Abstract][Full Text] [Related]
11. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
12. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I; Hirota S
Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
[TBL] [Abstract][Full Text] [Related]
14. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
Kuehnle I; Huls MH; Liu Z; Semmelmann M; Krance RA; Brenner MK; Rooney CM; Heslop HE
Blood; 2000 Feb; 95(4):1502-5. PubMed ID: 10666232
[TBL] [Abstract][Full Text] [Related]
15. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Corbacioglu S; Eber S; Gungor T; Hummerjohann J; Niggli F
J Pediatr Hematol Oncol; 2003 Apr; 25(4):327-9. PubMed ID: 12679650
[TBL] [Abstract][Full Text] [Related]
16. Antibody therapy for acute lymphoblastic leukemia.
Portell CA; Advani AS
Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as therapy for acute lymphoblastic leukemia.
Thomas DA
Clin Adv Hematol Oncol; 2010 Mar; 8(3):168-71. PubMed ID: 20400931
[No Abstract] [Full Text] [Related]
19. Novel targets for treatment of adult acute lymphocytic leukemia.
Kasner MT
Curr Hematol Malig Rep; 2010 Oct; 5(4):207-12. PubMed ID: 20680526
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.
Daver N; O'Brien S
Curr Hematol Malig Rep; 2013 Jun; 8(2):123-31. PubMed ID: 23539383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
